Table 1.

Patient data

Patient	Age/sex [years] [female/male]	Diagnosis	Quality of life [score]	Symptoms duration to PET 1 [years]	Clinical features 1: stance/gait/sitting ataxia 2: ocular motor dysfunction 3: dysarthria 4: limb ataxia	SARA PET 1 [points]	SARA PET 2 [points]	Delta SARA [points]	Responders
1	73 f	MSA-c	0.25	4	1,2,3,4	20	14	− 6	Yes
2	72 f	GAD-antibody encephalitis	0.5	3	1,2,4	16	10.5	− 5.5	Yes
3	28 m	Phenytoin associated CA	0.5	1	1,2,3,4	16	17.5	+ 1.5	No
4	45 f	Ethyl toxic	0.4	5	1,2,3,4	33	22.5	− 10.5	Yes
5	52 f	Ethyl toxic	0.7	3	1,2,3,4	17	14	− 3	Yes
6	75 m	MSA-c	0.3	4	1,2,3,4	12,5	9.5	− 3	Yes
7	42 f	SCA 3	0.6	6	1,2	4,5	2,5	− 2	No
8	61 f	SAOA	0.3	4	1,2,3,4	7	9	+ 2	No
9	69 f	SAOA, small ischaemia	0.2	9	1, 2,3,4	15,5	10	− 5.5	Yes
10	64 f	SAOA	0.3	13	1,2,3,4	12	–	–	–
11	64 m	SAOA	0.4	14	1,2,4	14,5	12	− 2.5	Yes
12	73 m	SAOA	0.8	12	1,2,4	8	8	8.0	No
13	74 f	SAOA with DBN	0.7	3	1,2,4	10,5	–	–	–
14	59 m	SCA 2	0.5	12	1,2,4	16	14.5	− 1.5	No
15	44 m	SCA 1	0.5	6	1,2,3,4	19	15.5	− 3.5	Yes
16	67 f	SAOA mit DBN	0.4	20	1,2,3,4	15,5	13.5	− 2.0	No
17	57 f	SAOA	0.5	7	1,2,3,4	13,5	6	− 7.5	Yes
18	69 m	Puratophin1-gene-mutation	0.6	9	1,2,3,4	12	8.5	− 3.5	Yes
19	74 m	SAOA	–	6	1,2	4,5	1.5	− 3.0	Yes
20	74 m	SAOA	–	5	1,2,4	13	12	− 1.0	No
21	49 f	Multiple sclerosis	0.6	2	1,2,3,4	10	7	− 3.0	Yes
22	77 f	SAOA with DBN	–	5	1,2	3	2	− 1.0	No
n = 22	61.9 ± 13.1 y		0.2–0.8	7.0 ± 5.5 y		Mean 13.3	Mean 10.5	Mean 4.5	Responders = 12
	f = 13		Mean 0.48	f = 13					Non-responders = 8
	m = 9								Drop out = 2

DBN downbeat nystagmus, GAD glutamate acid decarboxylase, MSAc multiple system atrophy of cerebellar dysfunction subtype, SCA spinocerebellar ataxia, SAOA sporadic adult-onset ataxia of unknown aetiology